Clinical ease of using doxazosin in BPH patients with and without hypertension.
Clinical studies have demonstrated that doxazosin therapy reduced blood pressure (BP) in patients with benign prostatic hyperplasia (BPH) who were hypertensive at baseline but not in patients who were physiologically or pharmacologically normotensive at baseline. In patients with BPH and uncontrolled hypertension, despite treatment with other antihypertensive drugs, the addition of doxazosin resulted in improved control with significant reductions in BP. The new formulation, doxazosin gastrointestinal therapeutic system (GITS), is initiated at a therapeutic dose, simplifying dose titration. Based on its efficacy and pharmacokinetic and tolerability profiles, doxazosin GITS is an effective and well-tolerated treatment for normotensive and hypertensive patients with BPH.
Steers
W D
WD
University of Virginia Hospital West, Charlottesville, Virginia 22908, USA. wds6t@virginia.edu
Kirby
R S
RS
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017292:Doxazosin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications*; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D017292:Doxazosin